CSE:CHGX - Post Discussion
Chitogenx Inc
> RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT CSE: ORTH
Post by
Betteryear2 on May 04, 2022 3:32pm
RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT CSE: ORTH
- New patent issued by U.S. Patent and Trademark Office to protect core IP until 2035
- Positions Company as leading player in the dynamic regenerative medicine market
- Enables delivery of PRP in soft tissue repair surgery in a proprietary way
MONTREAL, May 4, 2022 /PRNewswire/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho" or the "Company"), a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that the United States Patent and Trademark Office (the "USPTO") has issued a patent related to the Company's ORTHO-R soft tissue repair platform
https://www.prnewswire.com/news-releases/ortho-regenerative-technologies-receives-key-us-composition-and-method-patent-for-ortho-r-soft-tissue-repair-platform-301539419.html
Be the first to comment on this post